The Approved Live-Attenuated Chikungunya Virus Vaccine (IXCHIQ®) Elicits Cross-Neutralizing Antibody Breadth Extending to Multiple Arthritogenic Alphaviruses Similar to the Antibody Breadth Following Natural Infection
Vaccines · 07.08.2024 · 12 (8) · 893
DOI: 10.3390/vaccines12080893 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vaccines, online erschienen am 07.08.2024. Verfasst von Whitney C Weber und 16 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
The first vaccine against chikungunya virus (CHIKV) was recently licensed in the U.S., Europe, and Canada (brand IXCHIQ®, referred to as VLA1553). Other pathogenic alphaviruses co-circulate with CHIKV and major questions remain regarding the potential of IXCHIQ to confer cross-protection for populations that are exposed to them. Here, we characterized the cross-neutralizing antibody (nAb) responses against heterotypic CHIKV and additional arthritogenic alphaviruses in individuals at one month, six months, and one year post-IXCHIQ vaccination. We characterized nAbs against CHIKV strains LR2006, 181/25, and a 2021 isolate from Tocantins, Brazil, as well as O’nyong-nyong virus (ONNV), Mayaro virus (MAYV), and Ross River virus (RRV). IXCHIQ elicited 100% seroconversion to each virus, with the exception of RRV at 83.3% seroconversion of vaccinees, and cross-neutralizing antibody potency decreased with increasing genetic distance from CHIKV. We compared vaccinee responses to cross-nAbs elicited by natural CHIKV infection in individuals living in the endemic setting of Puerto Rico at 8–9 years post-infection. These data suggest that IXCHIQ efficiently and potently elicits cross-nAb breadth that extends to related alphaviruses in a manner similar to natural CHIKV infection, which may have important implications for individuals that are susceptible to alphavirus co-circulation in regions of potential vaccine rollout.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA.
- Department of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, OR 97239, USA.
- Ponce Research Institute, Ponce Health Sciences University, Ponce 00716, Puerto Rico.
- Valneva Austria GmbH, 1030 Vienna, Austria.
- Division of Pathobiology and Immunology, Oregon National Primate Research Center, Beaverton, OR 97006, USA.
ORCID-Profile: Whitney C Weber, Gauthami Sulgey, Dorca Marcano, Paola N Flores, Rachel M Rodriguez-Santiago, Vanessa Rivera-Amill, Karin Kosulin, Vera Buerger, Daniel N Streblow
Förderung
- NIAID NIH HHS
- NIH HHS
- NIGMS NIH HHS
- Valneva
- Valneva sponsored research agreement to OHSU (DNS)
- National Institutes of Health
Zitieren
APA
Weber, W. C., Streblow, Z. J., Kreklywich, C. N., Denton, M., Sulgey, G., Streblow, M. M., Marcano, D., Flores, P. N., Rodriguez-Santiago, R. M., Alvarado, L. I., Rivera-Amill, V., Messer, W. B., Hochreiter, R., Kosulin, K., Dubischar, K., Buerger, V., & Streblow, D. N. (2024). The Approved Live-Attenuated Chikungunya Virus Vaccine (IXCHIQ®) Elicits Cross-Neutralizing Antibody Breadth Extending to Multiple Arthritogenic Alphaviruses Similar to the Antibody Breadth Following Natural Infection. Vaccines, 12(8), 893. https://doi.org/10.3390/vaccines12080893
Vancouver
Weber WC, Streblow ZJ, Kreklywich CN, Denton M, Sulgey G, Streblow MM, et al. The Approved Live-Attenuated Chikungunya Virus Vaccine (IXCHIQ®) Elicits Cross-Neutralizing Antibody Breadth Extending to Multiple Arthritogenic Alphaviruses Similar to the Antibody Breadth Following Natural Infection. Vaccines. 2024;12(8):893. doi:10.3390/vaccines12080893
BibTeX
@article{Weber2024,
author = {Weber, Whitney C and Streblow, Zachary J and Kreklywich, Craig N and Denton, Michael and Sulgey, Gauthami and Streblow, Magdalene M and Marcano, Dorca and Flores, Paola N and Rodriguez-Santiago, Rachel M and Alvarado, Luisa I and Rivera-Amill, Vanessa and Messer, William B and Hochreiter, Romana and Kosulin, Karin and Dubischar, Katrin and Buerger, Vera and Streblow, Daniel N},
title = {The Approved Live-Attenuated Chikungunya Virus Vaccine (IXCHIQ®) Elicits Cross-Neutralizing Antibody Breadth Extending to Multiple Arthritogenic Alphaviruses Similar to the Antibody Breadth Following Natural Infection},
journal = {Vaccines},
year = {2024},
volume = {12},
number = {8},
pages = {893},
doi = {10.3390/vaccines12080893}
}
EUVIMED